Coriell Institute for Medical Research
Coriell Institute of Medical Research
  • Request a Quote
  • Donate
  • Login
  • View Cart
Sample Catalog | Custom Services | Core Facilities | Genomic Data Search
  • Biobank
    • NIGMS
    • NINDS
    • NIA
    • NHGRI
    • NEI
    • Allen Cell Collection
    • Rett Syndrome iPSC Collection
    • Autism Research Resource
    • HD Community Biorepository
    • CDC Cell and DNA
    • J. Craig Venter Institute
    • Orphan Disease Center Collection
    • All Biobanks
  • Research
    • Overview
    • Meet Our Scientists
      • Our Faculty
      • Our Scientific Staff
    • Camden Cancer Research Center
    • Epigenetic Therapies SPORE
    • Core Facilities
    • Epigenomics
    • Camden Opioid Research Initiative (CORI)
    • The Issa & Jelinek Lab
    • The Jian Huang Lab
    • The Luke Chen Lab
      • The Lab
      • The Team
      • Publications
    • The Scheinfeldt Lab
    • The Shumei Song Lab
    • The Nora Engel Lab
      • The Lab
      • The Team
      • Publications
    • Publications
  • Services
    • Overview
    • Biobanking Services
      • Core Services
      • Project Management
      • Research Support Services
      • Sample Cataloging
      • Sample Collection Kits
      • Sample Data Management
      • Sample Distribution
      • Sample Management
      • Sample Procurement
      • Sample Storage
    • Bioinformatics and Biostatistics Services
    • Cellular and Molecular Services
      • Biomarker Research Solutions
      • Cell Culture
      • Nucleic Acid Isolation and Quality Control
    • Clinical Trial Support
      • Overview
      • Sample Collection
      • Data Management
      • Sample Processing and QC
      • Storage and Distribution
      • Biomarker Services
      • Data Analaysis
    • Core Facilties
      • Overview
      • Animal and Xenograft
      • Bioinformatics and Biostatistics
      • Cell Imaging
      • CRISPR Gene Engineering
      • Flow Cytometry and Cell Sorting
      • Genomics and Epigenomics
      • iPSC - Induced Pluripotent Stem Cells
      • Organoids
    • Coriell Marketplace
    • Genomic, Epigenomic and Multiomics Services
    • Stem Cells and iPSC Services
      • Core Services
      • Reprogramming
      • Characterization and Quality Control
      • Differentiated Cell Lines
      • iPSC-Derived Organoids
      • iPSC Expansion
      • iPSC Gene Editing
  • Ordering
    • Stem Cells
    • Cell Lines
    • DNA and RNA
    • Featured Products
      • FFPE
      • HMW DNA
    • Genomic Data Search
    • Search by Catalog ID
    • Help
      • Create Account
      • Order Online
      • Ordering FAQ
      • FAQs/Culture Instructions
      • Reference Materials
        • Biobanks
        • NIGMS Repository
        • NHGRI Repository
        • NINDS Repository
        • NIA Repository
        • NIST
        • GeT-RM
      • Secondary Distribution Policies
      • MTA Assurance Form
      • Shipment Policy
      • Contact Customer Service
  • About Us
    • Our History
    • Meet Our Team
    • Meet Our Board
    • Education
      • Science Fair
      • Summer Experience
      • Outreach
      • Research Program Internship
    • Press Room
      • Press Releases
      • Coriell Blog
      • Annual Report
    • Careers
      • Working at Coriell
    • Giving
      • Donate
      • Giving FAQ
    • Contact Us
    • Legal Notice
  • Login View Cart
search submit
NA01715 DNA from LCL

Description:

SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE, B CELL-NEGATIVE, NK CELL-NEGATIVE, DUE TO ADENOSINE DEAMINASE DEFICIENCY
ADENOSINE DEAMINASE; ADA

Affected:

Yes

Sex:

Male

Age:

3 YR (At Sampling)

  • Overview
  • Characterizations
  • Phenotypic Data
  • Publications
  • External Links

Overview

back to top
Repository NIGMS Human Genetic Cell Repository
Subcollection Heritable Diseases
Class Disorders of Nucleotide and Nucleic Acid Metabolism
Quantity 25 µg
Quantitation Method Please see our FAQ
Biopsy Source Peripheral vein
Cell Type B-Lymphocyte
Tissue Type Blood
Transformant Epstein-Barr Virus
Sample Source DNA from LCL
Race Black/African American
Family Member 1
Relation to Proband proband
Confirmation Clinical summary/Case history
Species Homo sapiens
Common Name Human
Remarks Clinically affected; failure to thrive; multiple pneumonias and oral/skin moniliasis; long-term hospitalization starting at age 26 months: immunologic studies showed variable but persistent lymphopenia, low numbers of T lymphocytes, relatively increased percentage of B lymphocytes, bone marrow aspirate with few lymphocytes or plasma cells, lymph node biopsy revealed a "hypoplastic node with follicles but largely absent T-dependent areas and sinus histiocytosis", quantitative immunoglobins remained normal; height and weight increased to 25th-50th percentile by age 6 years but subject remained lymphopenic; between ages 11-14 years the absolute lymphocyte count was normal with a normal percentage of T cells; no medical problems at age 20 years (no theapy from age 13-20 years); HLA type A2,30,B7,39; enzyme phenotypes: 6PGD=A, G6PD=A, Peptidases A,C,&D=1, Acid A-glucosidase=1, Neutral A-glucosidase C=3, & GLO-1=2; 46,XY; ADA activity shortly after diagnosis was 1% of normal in erythrocytes and 18% of normal in mixed mononuclear cells; ADA in both cultured lymphoid and fibroblast cell lines established at diagnosis showed deficiency of ADA with <1% of normal ADA activity; a lymphoid cell line established at age 16 years exhibited >50% of normal ADA activity; studies performed on the lymphoid and fibroblast cell lines established at the time of diagnosis found the donor subject to be a compound heterozygote: one allele has a G>A transition at nucleotide 302 in exon 4 of the ADA gene [302G>A] resulting in a substitution of glutamine for arginine at codon 101 [Arg101Gln(R101Q)] and a second allele has a splice-donor-site mutation in IVS1(+1GT>CT) resulting in an unstable mRNA; the B cell line expressing ADA activity (established at age 16 years) contained the missense Arg101Gln mutation but lacked the splice-site mutation; donor subject determined to have somatic mosaicism; same donor as GM02445 fibroblast.

Characterizations

back to top
IDENTIFICATION OF SPECIES OF ORIGIN Species of Origin Confirmed by Chromosome Analysis
 
MUTATION VERIFICATION Bonthron et al (J Clin Invest 76:894-897 1985) reported the cloning and sequence analysis of full-length cDNAs from this ADA-deficient cell line. Four apparently identical though independently isolated clones were sequenced. In each a G to A mutation at base number 302 of the coding sequence was found which predicts a glutamine residue to be substituted for arginine in the ADA protein at codon 101. The authors believed that only one of the defective alleles in this cell line had been sequenced.
 
adenosine deaminase According to the submitter, biochemical test results for this subject showed decreased enzyme activity. EC Number: 3.5.4.4; 1% activity.
 
Gene ADA
Chromosomal Location 20q13.11
Allelic Variant 1 608958.0003; SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE, B CELL-NEGATIVE, NK CELL-NEGATIVE, DUE TO ADENOSINE DEAMINASE DEFICIENCY
Identified Mutation ARG101GLN; In cell line GM01715 from an immunodeficient patient, Bonthron et al. [J Clin Invest 76: 894(1985)] found a point mutation in codon 101 (CGG to CAG) of ADA; this change predicts an amino acid change from arginine to glutamine. The mutation was apparently responsible for loss of function in the gene because the predicted primary structure of the enzyme was otherwise entirely normal. The demonstration of 2 different mutations in codon 101 leading to ADA deficiency indicates that this amino acid position is critical for stability and/or activity of the enzyme protein.
 
Gene ADA
Chromosomal Location 20q13.11
Allelic Variant 2 608958.0024; SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE, B CELL-NEGATIVE, NK CELL-NEGATIVE, DUE TO ADENOSINE DEAMINASE DEFICIENCY
Identified Mutation IVS1DS, G>C, +1; Hirschhorn et al. [Ann Hum Genet 58: 1 (1994)] found that fibroblast and B-cell lines established at the time of diagnosis of ADA deficiency (GM02445 and GM01715) were heteroallelic for a newly identified splice site mutation (+1 GT-to-CT transversion) at the donor splice site in IVS1 and for a previously described arg101-to-gln missense mutation in exon 4 (102700.0003). As described earlier, by the time the patient was 16 years of age, the mutation had disappeared from the B cells but not from the fibroblasts and the patient had undergone spontaneous recovery from ADA deficiency.

Phenotypic Data

back to top
Remarks Clinically affected; failure to thrive; multiple pneumonias and oral/skin moniliasis; long-term hospitalization starting at age 26 months: immunologic studies showed variable but persistent lymphopenia, low numbers of T lymphocytes, relatively increased percentage of B lymphocytes, bone marrow aspirate with few lymphocytes or plasma cells, lymph node biopsy revealed a "hypoplastic node with follicles but largely absent T-dependent areas and sinus histiocytosis", quantitative immunoglobins remained normal; height and weight increased to 25th-50th percentile by age 6 years but subject remained lymphopenic; between ages 11-14 years the absolute lymphocyte count was normal with a normal percentage of T cells; no medical problems at age 20 years (no theapy from age 13-20 years); HLA type A2,30,B7,39; enzyme phenotypes: 6PGD=A, G6PD=A, Peptidases A,C,&D=1, Acid A-glucosidase=1, Neutral A-glucosidase C=3, & GLO-1=2; 46,XY; ADA activity shortly after diagnosis was 1% of normal in erythrocytes and 18% of normal in mixed mononuclear cells; ADA in both cultured lymphoid and fibroblast cell lines established at diagnosis showed deficiency of ADA with <1% of normal ADA activity; a lymphoid cell line established at age 16 years exhibited >50% of normal ADA activity; studies performed on the lymphoid and fibroblast cell lines established at the time of diagnosis found the donor subject to be a compound heterozygote: one allele has a G>A transition at nucleotide 302 in exon 4 of the ADA gene [302G>A] resulting in a substitution of glutamine for arginine at codon 101 [Arg101Gln(R101Q)] and a second allele has a splice-donor-site mutation in IVS1(+1GT>CT) resulting in an unstable mRNA; the B cell line expressing ADA activity (established at age 16 years) contained the missense Arg101Gln mutation but lacked the splice-site mutation; donor subject determined to have somatic mosaicism; same donor as GM02445 fibroblast.

Publications

back to top
Hirschhorn R, Yang DR, Israni A, Huie ML, Ownby DR, Somatic mosaicism for a newly identified splice-site mutation in a patient with adenosine deaminase-deficient immunodeficiency and spontaneous clinical recovery. Am J Hum Genet55(1):59-68 1994
PubMed ID: 8023852
 
Hirschhorn R, Ellenbogen A, Tzall SHirschhorn, Five missense mutations at the adenosine deaminase locus (ADA) detected by altered restriction fragments and their frequency in ADA--patients with severe combined immunodeficiency (ADA-SCID). Am J Hum Genet42:201-7 1992
PubMed ID: 1346349
 
Hirschhorn R, Chakravarti V, Puck J, Douglas SD, Homozygosity for a newly identified missense mutation in a patient with very severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID). Am J Hum Genet49:878-85 1991
PubMed ID: 1680289
 
Tzall S, Ellenbogen A, Eng F, Hirschhorn R, Identification and characterization of nine RFLPs at the adenosine deaminase (ADA) locus. Am J Hum Genet44:864-75 1989
PubMed ID: 2567118
 
Akeson AL, Wiginton DA, Dusing MR, States JC, Hutton JJ, Mutant human adenosine deaminase alleles and their expression by transfection into fibroblasts. J Biol Chem263:16291-6 1988
PubMed ID: 3182793
 
Akeson AL, Wiginton DA, States JC, Perme CM, Dusing MR, Hutton JJ, Mutations in the human adenosine deaminase gene that affect protein structure and RNA splicing. Proc Natl Acad Sci U S A84:5947-51 1987
PubMed ID: 3475710
 
Berkvens TM, Gerritsen EJ, Oldenburg M, Breukel C, Wijnen JT, van Ormondt H, Vossen JM, van der Eb AJ, Meera Khan P, Severe combined immune deficiency due to a homozygous 3.2-kb deletion spanning the promoter and first exon of the adenosine deaminase gene. Nucleic Acids Res15:9365-78 1987
PubMed ID: 3684597
 
Valerio D, Dekker BM, Duyvesteyn MG, van der Voorn L, Berkvens TM, van Ormondt H, van der Eb AJ, One adenosine deaminase allele in a patient with severe combined immunodeficiency contains a point mutation abolishing enzyme activity. EMBO J5:113-9 1986
PubMed ID: 3007108
 
Bonthron DT, Markham AF, Ginsburg D, Orkin SH, Identification of a point mutation in the adenosine deaminase gene responsible for immunodeficiency. J Clin Invest76:894-7 1985
PubMed ID: 3839802
 
Daddona PE, Shewach DS, Kelley WN, Argos P, Markham AF, Orkin SH, Human adenosine deaminase. cDNA and complete primary amino acid sequence. J Biol Chem259:12101-6 1984
PubMed ID: 6090454
 
Valerio D, Duyvesteyn MG, van Ormondt H, Meera Khan P, van der Eb AJ, Adenosine deaminase (ADA) deficiency in cells derived from humans with severe combined immunodeficiency is due to an aberration of the ADA protein. Nucleic Acids Res12:1015-24 1984
PubMed ID: 6198631
 
Hirschhorn R, Roegner V, Jenkins T, Seaman C, Piomelli S, Borkowsky W, Erythrocyte adenosine deaminase deficiency without immunodeficiency. Evidence for an unstable mutant enzyme. J Clin Invest64:1130-9 1979
PubMed ID: 479373
 
Wolf, Syndrome of cellular immunodeficiency with immunoglobulins associated with adenosine deaminase deficiency. Pediatr Res10:394 (1976):1130-9 1976
PubMed ID: 479373

External Links

back to top
dbSNP dbSNP ID: 21995
Gene Cards ADA
Gene Ontology GO:0004000 adenosine deaminase activity
GO:0009117 nucleotide metabolism
GO:0009168 purine ribonucleoside monophosphate biosynthesis
GO:0016787 hydrolase activity
GO:0019735 antimicrobial humoral response (sensu Vertebrata)
NCBI Gene Gene ID:100
NCBI GTR 102700 SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE, B CELL-NEGATIVE, NK CELL-NEGATIVE, DUE TO ADENOSINE DEAMINASE DEFICIENCY
608958 ADENOSINE DEAMINASE; ADA
OMIM 102700 SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE, B CELL-NEGATIVE, NK CELL-NEGATIVE, DUE TO ADENOSINE DEAMINASE DEFICIENCY
608958 ADENOSINE DEAMINASE; ADA
Omim Description ADA-SCID, INCLUDED
  ADENOSINE AMINOHYDROLASESEVERE COMBINED IMMUNODEFICIENCY DUE TO ADENOSINE DEAMINASE DEFICIENCY,INCLUDED
  ADENOSINE DEAMINASE; ADA
  SCID DUE TO ADA DEFICIENCY, INCLUDED
Pricing
International/Commercial/For-profit:
$281.00USD
U.S. Academic/Non-profit/Government:
$139.00USD
Add to Cart
How to Order
  • Ordering Instructions
  • MTA / Assurance Form
  • Statement of Research Intent Form
Related Products
Same Subject
  • GM01715 - B-Lymphocyte
Same Family
  • 423
Miscellaneous
  • Custom Services

Our mission is to prevent and cure disease through biomedical research.

CONTACT US

CUSTOMER SERVICE
customerservice@coriell.org (800) 752-3805 • (856) 757-4848
Subscribe to our newsletter here

Coriell Institute for Medical Research
403 Haddon Avenue Camden, NJ 08103, USA (856) 966-7377

Ⓒ 2025 Coriell Institute. All rights reserved.

  • Facebook
  • Linkedin
  • Youtube